Azafaros B.V., headquartered in Leiden, The Netherlands, has recently incorporated a Swiss subsidiary in the pharma hub of Basel to strengthen its research and development operations. In addition, three experienced industry executives have joined the Company. Kyle Landskroner, Ph.D., has been appointed Head of Preclinical Drug Development, Ruben Giorgino, M.D., Ph.D., has been appointed Head of Clinical Research and Development and Louise Kooij, M.S., joins as Head of Finance and Operations. The new members together with Chief Executive Officer, Olivier Morand, Ph.D., form the Azafaros executive management team.
With this new company development, Azafaros is well positioned to advance the Company's pipeline focused on innovative treatments for rare inherited metabolic diseases, for which there are no effective therapies today.
Azafaros is supported by a syndicate of leading Dutch and Swiss investors including Forbion, BioGeneration Ventures, BioMedPartners and Schroder Adveq.
VISCHER advised on all Swiss legal issues related to the transaction. The VISCHER team included Christian Wyss (Partner, Life Sciences), Timothy Woodtli (Associate, Corporate/M&A), Francesca Pesenti (Associate, Corporate/M&A), and Gian Geel (Associate, Employment).